NCT07211932
Tofacitinib in Juvenile Idiopathic Arthritis
StatusRecruiting
PhaseNot specified
Primary completion (estimated)
At risk: Primary completion moved at least 11 months later.
See at-risk trials from Consorci Sanitari de l'Alt Penedès i Garraf
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 2 with changes below, 1 re-verified with no change.
- Notable Primary and study completion pushed from Dec 2026 to Dec 2027
- Recruitment opened
- Trial sites expanded: 3 → 7 locations
- Start date changed from estimate of Dec 2025 to Feb 2, 2026
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
JADAS-10
Timeframe: Baseline and 12 months
Arms and interventions
Tofacitinib
Patients affected by JIA and treated with tofacitinib
Drugs: Tofacitinib
Sites
7 sites in 1 country